Abstract 1739P
Background
According to the American Cancer Society, lung cancer is the leading cause of cancer-related deaths globally, and tobacco use is the 1ry cause of the disease. The association between tobacco use and lung cancer is well recognized, with smoking cigarettes accounting for approximately 85% of all lung cancer cases. Despite significant public health efforts to reduce tobacco use, it remains a prevalent issue, with an estimated 14% of the U.S. adult population being current smokers. Therefore, there is a continued need to investigate the relationship between tobacco use and lung cancer to better establish public health interventions and policies that can reduce the burden of this deadly disease.
Methods
Using the CDC multiple causes of death database (ICD-10 revision codes), we identified all patients with history of tobacco use who died of lung cancer (C34.x registered as the underlying cause of death) in Caucasian, African American, Asian, American Indian races, between 1999 and 2020 in the United States. Age-adjusted mortality rates were calculated per 1,000,000 persons (PMP), standardized to the U.S. census data from 1999, and stratified by gender.
Results
Between 1999 and 2020, 1,084,140 deaths were due to lung cancer in persons with history of tobacco use (age-adjusted mortality= 144.6 PMP). We identified a total of 970,370 Caucasian, 96,001 African American, 11,279 Asian, and 6,490 American Indian deaths in each population (total age-adjusted mortality was 151.5 PMP, 129.5 PMP, 38.3 PMP, and 117.7, respectively). Over 21 years, age-adjusted mortality increased by 782% in Caucasians (19.5 PMP in 1999 to 152.4 PMP in 2020), 575% in African Americans (21.2 PMP in 1999 to 121.9 PMP in 2020), 724% in Asians (5 PMP in 1999 to 36.2 PMP in 2020), and 351% in American Indians (27.2 PMP in 1999 to 95.5 PMP in 2020).
Conclusions
The study's results show a significant and consistent rise in the mortality rates of tobacco-related lung cancer among all ethnicities, ranging from 351% in American Indians to 782% in Caucasians. These findings emphasize the urgent need for effective public health interventions and policies that can address the destructive impact of tobacco use on lung cancer mortality across all racial groups in the U.S.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1912TiP - STELLAR-304: A randomized phase III study of zanzalintinib (XL092) and nivolumab in non-clear cell renal cell carcinoma (nccRCC)
Presenter: Sumanta Pal
Session: Poster session 23
2366P - Phase I-II study of niraparib plus cabozantinib in patients with advanced urothelial/kidney cancer (NICARAGUA trial)
Presenter: Daniel Castellano Gauna
Session: Poster session 23
2367P - A randomized phase II study of atezolizumab (atezo) plus recombinant human IL-7 (CYT107) vs. atezo alone in patients with locally advanced or metastatic urothelial carcinoma (mUC)
Presenter: Russells Pachynski
Session: Poster session 23
2368P - Activity of cabozantinib (CABO) plus durvalumab (DURVA) in patients (pts) with advanced non-urothelial-carcinoma variant histologies (VHs) or urothelial carcinoma (UC) after platinum-based chemotherapy: Interim results from the phase II ARCADIA trial
Presenter: Patrizia Giannatempo
Session: Poster session 23
2369P - Phase II study of nivolumab (nivo) and ipilimumab (ipi) for advanced bladder cancer with variant histologies (BCVH)
Presenter: Bradley McGregor
Session: Poster session 23
2370P - Updated results of PEANUT trial: Pembrolizumab and nab-paclitaxel as salvage therapy for platinum-treated, locally advanced or metastatic urothelial carcinoma (mUC)
Presenter: Achille Bottiglieri
Session: Poster session 23
2371P - Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (aUC): Long-term outcomes from the JAVELIN Bladder 100 trial in older patients (pts)
Presenter: Shilpa Gupta
Session: Poster session 23
2372P - Efficacy of a tailored approach with nivolumab (N) and nivolumab+ipilimumab (N+I) as immuno-therapeutic boost in metastatic urothelial carcinoma (mUC): Final results of TITAN-TCC
Presenter: Marc-Oliver Grimm
Session: Poster session 23
2373P - Outcomes by retrospective eligibility for maintenance therapy of patients (pts) with advanced urothelial carcinoma (UC): Post hoc analysis of KEYNOTE-361
Presenter: Ronac Mamtani
Session: Poster session 23
2374P - A phase Ib single-arm trial of bintrafusp alfa (BA) for pretreated, locally advanced/unresectable or metastatic (advanced) urothelial cancer (aUC)
Presenter: Petros Grivas
Session: Poster session 23